ARA-290

ARA-290 (cibinetide) is a synthetic 11-amino-acid linear peptide with the sequence pyroglutamate-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (pGlu-EQLERALNSS) and molecular weight 1257 Da. It was engineered from the helix B surface domain of erythropoietin (EPO) by Michael Brines and Anthony Cerami at Araim Pharmaceuticals. The compound represents a deliberate molecular dissection of EPO's two distinct biological functions: erythropoiesis (red blood cell production) and tissue protection.

The conceptual breakthrough underlying ARA-290 development was the recognition that native EPO has two distinct receptor interactions producing different biological effects. The classical EPO receptor (EPOR) forms a homodimer (EPOR/EPOR) on erythroid progenitor cells; activation by EPO drives erythropoiesis. A separate heterodimeric complex composed of EPOR plus the beta-common receptor (also called CD131) was identified by Brines and Cerami as the "innate repair receptor" (IRR) mediating tissue-protective and anti-inflammatory signaling. The IRR is upregulated on tissues under stress or injury, providing a localized response mechanism that does not require systemic erythropoietic effects.

EPO has substantial tissue-protective and anti-inflammatory activity in animal models of stroke, myocardial infarction, kidney injury, and neuropathy. However, the erythropoietic effects of EPO produce cardiovascular risks (elevated hematocrit, blood viscosity, hypertension, thrombosis) that limit its clinical use for tissue protection. ARA-290 was engineered to capture only the IRR-mediated tissue-protective signaling, providing EPO's regenerative benefits without its cardiovascular liabilities.

The Evidence

Brines et al., 2008. Original characterization of nonerythropoietic tissue-protective peptides derived from EPO tertiary structure. The paper established the structural basis for separating IRR activation from EPO receptor activation through peptide engineering.

Dahan et al., 2013. Phase 2 trial of cibinetide in chronic neuropathic pain from sarcoidosis demonstrated improvement in pain scores and quality of life measures.

Heij et al., 2018 — DOSARA trial. Phase 2b trial in 64 patients with sarcoidosis-associated small fiber neuropathy. Patients received 4 mg subcutaneous cibinetide daily for 28 days. The 4 mg dose group showed a 23 percent increase in corneal nerve fiber area versus baseline, confirmed by corneal confocal microscopy. Neuropathic pain scores and autonomic symptoms also improved. The trial supported FDA Orphan Drug designation.

Mechanism characterization. The Brines and Cerami group has published extensively on IRR biology, demonstrating CD131 as the critical co-receptor component, mapping IRR expression in tissue injury models, and showing that CD131-knockout animals lose ARA-290's tissue-protective effects but retain normal erythropoiesis.

Broader trial program. Cibinetide has been evaluated in additional contexts including diabetic peripheral neuropathy, cardiac ischemia-reperfusion injury, and other tissue-injury settings. Results have been generally favorable but have not progressed to Phase 3 completion in any indication as of May 2026.

Regulatory and Legal Status

FDA. Orphan Drug designation for sarcoidosis-associated small fiber neuropathy. No marketing authorization.

EMA. EU Orphan Drug Designation for treatment of sarcoidosis. Not approved as a medicinal product in any EU member state.

Phase of development. Phase 2 complete. No Phase 3 trial results publicly reported as of May 2026.

Compounding. Not on FDA bulk drug substances list.

WADA. Not specifically on 2026 Prohibited List. The EPO-derived structure could attract regulatory attention despite the mechanistic difference from erythropoietic EPO.

Research-chemical availability. Some vendors offer ARA-290-labeled product. Identity verification is the buyer's responsibility.

ARA-290 is a selective agonist of the innate repair receptor without erythropoietic activity.

Innate repair receptor (IRR) biology. The IRR is a heterodimeric receptor complex composed of the classical EPO receptor (EPOR) plus the beta-common receptor (also called CD131 or beta-cR). Unlike the EPOR/EPOR homodimer that drives erythropoiesis, the heterodimer is:

• Selectively expressed on tissues under stress or injury (not constitutively present)
• Upregulated by inflammatory and ischemic signals
• Responsible for tissue-protective and anti-inflammatory signaling
• Active at much lower agonist concentrations than the EPOR homodimer

ARA-290 selectivity. The peptide reproduces only the surface of EPO that engages the IRR. The classical EPOR homodimer requires additional structural features of full EPO that are absent in ARA-290. The result is that ARA-290 engages the IRR with reasonable affinity while showing no activity at the EPOR homodimer at physiologically relevant concentrations.

Downstream IRR signaling. Activated IRR signals through several pathways:

• Anti-inflammatory effects through suppression of pro-inflammatory cytokine production
• Anti-apoptotic effects in cells under stress
• Pro-regenerative effects supporting tissue repair and nerve fiber regeneration
• Vascular effects improving endothelial function and microcirculation
• Metabolic effects improving glucose and lipid handling in some models

Mechanistic basis for selectivity vs EPO. Animals genetically lacking CD131 lose all ARA-290 tissue-protective effects but retain normal erythropoiesis through the EPOR homodimer. Conversely, ARA-290 administration produces tissue protection without any change in hematocrit, hemoglobin, or red blood cell parameters. This double dissociation confirms the mechanistic separation.

Pharmacokinetics. Plasma half-life is approximately 20 minutes. The short circulating half-life would seem inadequate for sustained tissue protection. The proposed model is that ARA-290 acts as a "molecular switch" triggering tissue repair pathways that persist beyond the agent's clearance. This is consistent with the clinical observation that effects develop over weeks of daily dosing despite minute-scale circulating half-life.

Tissue-specific expression of IRR. The IRR is upregulated in tissues under stress (ischemic brain, injured kidney, damaged peripheral nerve, inflamed tissues) but minimally expressed in healthy tissues. This provides a degree of tissue selectivity beyond the receptor specificity, with ARA-290 acting preferentially on injured tissues rather than healthy ones.

Phase 2 trial and animal model effects documented in published work:

• Increase in corneal nerve fiber density in sarcoidosis-associated small fiber neuropathy
• Reduction in neuropathic pain scores
• Improvement in autonomic dysfunction markers
• Anti-inflammatory effects in tissue injury models
• Tissue protection in cardiac ischemia-reperfusion animal models
• Kidney protection in animal AKI models
• Effects on glucose homeostasis in diabetic neuropathy models
• Absence of cardiovascular risks associated with EPO (no hematocrit elevation, no thrombosis signal)

Research-chemical user reports describe subjective improvements in pain conditions, anti-inflammatory effects, and recovery from injury. Reports are anecdotal, uncontrolled, and not verified for vial identity. The clinical trial evidence base is among the stronger in the experimental peptide category, but Phase 3 confirmation has not been completed.

Clinical trial dosing:

• 4 mg subcutaneous daily for 28 days (DOSARA trial standard)
• Research extensions: 4 mg subcutaneous daily for up to 12 weeks
• Reconstitution: typically to 4 mg/mL concentration with bacteriostatic water
• Administration: subcutaneous via insulin syringe

The dosing schedule is daily despite the short plasma half-life, consistent with the "molecular switch" mechanism proposing that brief receptor activation triggers sustained tissue repair pathways.

Research-chemical user protocols typically follow the clinical trial dosing pattern at 2 to 4 mg per day subcutaneous over multi-week cycles. The dosing has reasonable clinical trial support compared with many research-chemical peptides where dose recommendations are extrapolated from rodent models.

The 28-day cycle length used in clinical trials provides a reasonable framework for research-chemical use, though optimal cycle spacing and number of cycles per year have not been formally studied.

Phase 2 clinical trials have reported generally well-tolerated administration:

• Mild injection site reactions
• Occasional headache
• Minor gastrointestinal discomfort
• No significant cardiovascular adverse events
• No hematologic changes (no hematocrit elevation, no thrombosis signal)
• No erythropoietic effects despite EPO structural origin

Important safety distinction. Unlike EPO, ARA-290 does not produce the cardiovascular risks that limit EPO use for tissue protection. The absence of erythropoiesis is the central safety advantage and is supported by clinical trial data showing no hematocrit changes.

Long-term safety beyond Phase 2 trial follow-up is not characterized.

Theoretical concerns based on mechanism:

• Effects with very long-term use on tissue homeostasis are unknown
• Drug-drug interactions with anti-inflammatory medications, immunosuppressants, and other tissue-modulating agents have not been formally studied
• Effects in pregnancy and lactation have not been formally evaluated
• Effects in patients with cancer (theoretical concern about tissue-protective effects on tumor tissue) are uncharacterized; CD131 is expressed on some tumor types
• Effects on wound healing in surgical contexts could be relevant for pre-operative use

The safety profile is among the more favorable in the experimental peptide category, with Phase 2 data supporting acceptable tolerability. Phase 3 trials would normally extend the safety database substantially.

ARA-290 occupies a relatively unique mechanistic niche (IRR agonism) without close peers in the established peptide landscape. The closest research-chemical category companions are:

• BPC-157 and TB-500 for broader tissue healing through different mechanisms
• B7-33 for anti-fibrotic effects through RXFP1
• Pentadeca-Arginate as a newer tissue-healing peptide variant
• Methylene Blue for broader cytoprotective effects through different pathways

For users with specific clinical interest in neuropathy:

• For diabetic peripheral neuropathy: pregabalin, gabapentin, duloxetine, amitriptyline (FDA-approved or established off-label)
• For sarcoidosis: corticosteroids, methotrexate, hydroxychloroquine, TNF inhibitors (infliximab, adalimumab); cibinetide remains investigational
• For chronic neuropathic pain generally: established neuromodulators plus topical agents (capsaicin, lidocaine)

ARA-290's distinctive position is the combination of clinical trial validation in a specific indication (sarcoidosis SFN), Orphan Drug regulatory recognition, and favorable safety profile compared with many experimental peptides. For users with sarcoidosis-associated small fiber neuropathy specifically, the compound has more relevant evidence than most research-chemical peptides have for any indication. For other applications, the evidence base is preliminary or absent.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.